Reynaert 1995.

Methods	Six‐week randomised, double‐blind study
Participants	In‐ and outpatients fulfilling DSM‐III‐R criteria for major depressive disorder, with a score of at least 16 on the Hamilton Rating Scale for Depression‐17 item (HDRS‐17). Mean age: 47 years Exclusion criteria: suicide risk, any other psychiatric illness, severe organic disease, alcoholism and drug abuse, use of MAOI in the previous 2 weeks and antidepressants in the previous 4 days or any investigational drugs in the previous 4 weeks, use in the past of fluoxetine or moclobemide.
Interventions	Fluoxetine: 50 participants Moclobemide: 51 participants Fluoxetine dose range: 20‐40 mg/day Moclobemide dose range: 300‐600 mg/day Lithium and one benzodiazepine were permitted
Outcomes	Primary outcomes: HDRS‐17, Clinical Global Impression (CGI)
Notes	Response: decrease of at least 50% in the total score or a score of maximum 10 on the HDRS‐17 Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Number and reasons for dropout were reported. Denominator reported for responders was different from the number of randomised patients
Selective reporting (reporting bias)	Unclear risk	Secondary outcomes not reported. Side effects and vital signs not clearly reported
Other bias	High risk	Last author's affiliation is Roche S. A., Brussels, Belgium and this company produces moclobemide